What I find to be interesting in the book is the dance between WS "analysts" and the company. How VRTX as a perennial cash starved company played WS like a string to finance itself over the yrs.
I confirmed my opinion that much of WS "Analysis" is pretty much guess work generally spiced with overoptimism.
After so many B$ spent, Vrtx is still not a profitable concern. I am afraid most of the Biotech Values or non Values , will never become profitable ; most trade on hot air and the hope of a BO by a bigger pharma
Market Data 
Markets 
AI
